Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research
- PMID: 24488689
- DOI: 10.1002/mus.24198
Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research
Abstract
Genetic insights into the pathophysiology of amyotrophic lateral sclerosis (ALS) are untangling the clinical heterogeneity that may contribute to poor clinical trial outcomes and thus to a lack of effective treatments. Mutations in a large number of genes, including SOD1, C9ORF72, TARDBP, FUS, VAPB, VCP, UBQLN2, ALS2, SETX, OPTN, ANG, and SPG11, are thought to cause ALS, whereas others, including ATAXN2, GRN, HFE, NEFH, UNC13A, and VEGF, appear to be disease-modifying genes. Epigenetic influences may also play important roles. An improved understanding of ALS genetics should lead to better trial designs, insights into common molecular pathways, and better characterization of preclinical models. New genetic sequencing techniques, which use high-throughput methods to assess variants across the genome or exome, may facilitate rational patient stratification for clinical trials and permit more individualized prognostic information and treatment decisions in clinical care. Muscle Nerve 49: 786-803, 2014.
Keywords: amyotrophic lateral sclerosis; clinical trials; genetics; genomics; personalized medicine.
Copyright © 2014 Wiley Periodicals, Inc.
Similar articles
-
Identify mutation in amyotrophic lateral sclerosis cases using HaloPlex target enrichment system.Neurobiol Aging. 2014 Dec;35(12):2881.e11-2881.e15. doi: 10.1016/j.neurobiolaging.2014.07.003. Epub 2014 Jul 11. Neurobiol Aging. 2014. PMID: 25109764
-
Amyotrophic Lateral Sclerosis Overview.2001 Mar 23 [updated 2023 Sep 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2001 Mar 23 [updated 2023 Sep 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301623 Free Books & Documents. Review.
-
Evidence for an oligogenic basis of amyotrophic lateral sclerosis.Hum Mol Genet. 2012 Sep 1;21(17):3776-84. doi: 10.1093/hmg/dds199. Epub 2012 May 29. Hum Mol Genet. 2012. PMID: 22645277
-
Novel FUS deletion in a patient with juvenile amyotrophic lateral sclerosis.Arch Neurol. 2012 May;69(5):653-6. doi: 10.1001/archneurol.2011.2499. Arch Neurol. 2012. PMID: 22248478
-
Clinical and genetic heterogeneity of amyotrophic lateral sclerosis.Clin Genet. 2013 May;83(5):408-16. doi: 10.1111/cge.12117. Epub 2013 Mar 12. Clin Genet. 2013. PMID: 23379621 Review.
Cited by
-
iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease Development.J Clin Med. 2014 Oct 17;3(4):1124-45. doi: 10.3390/jcm3041124. J Clin Med. 2014. PMID: 26237595 Free PMC article. Review.
-
Munc13 Is a Molecular Target of Bryostatin 1.Biochemistry. 2019 Jul 9;58(27):3016-3030. doi: 10.1021/acs.biochem.9b00427. Epub 2019 Jun 20. Biochemistry. 2019. PMID: 31243993 Free PMC article.
-
Genetic diagnosis and detection rates using C9orf72 repeat expansion and a multi-gene panel in amyotrophic lateral sclerosis.J Neurol. 2024 Jul;271(7):4258-4266. doi: 10.1007/s00415-024-12368-3. Epub 2024 Apr 16. J Neurol. 2024. PMID: 38625400
-
Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases.Sci Adv. 2022 Apr 8;8(14):eabl4370. doi: 10.1126/sciadv.abl4370. Epub 2022 Apr 8. Sci Adv. 2022. PMID: 35394834 Free PMC article.
-
Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis.EBioMedicine. 2018 Jul;33:169-184. doi: 10.1016/j.ebiom.2018.06.015. Epub 2018 Jun 23. EBioMedicine. 2018. PMID: 29941342 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
